Featured Press Releases

Smart Cups Sets New Goals For Fundraising Round Amid Upcoming Partnerships And Continued Growth

Smart Cups Sets New Goals For Fundraising Round Amid Upcoming Partnerships And Continued Growth

Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies

Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies

  • 18 Apr 2024

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to...

The iPSCore™ platform, developed by iXCells Biotechnologies, enables the generation of highly characterized iPSC-derived human cell models

The iPSCore™ platform, developed by iXCells Biotechnologies, enables the generation of highly characterized iPSC-derived human cell models

Kashiv BioSciences Announces Positive Topline Results from the Confirmatory Efficacy Study of ADL-018, a Biosimilar Candidate to XOLAIR® (omalizumab).

Kashiv BioSciences Announces Positive Topline Results from the Confirmatory Efficacy Study of ADL-018, a Biosimilar Candidate to XOLAIR® (omalizumab).

Neurocrine Biosciences begins Phase 1 trial on NBI-1065890, a second-gen VMAT2 inhibitor, in healthy adults

Neurocrine Biosciences begins Phase 1 trial on NBI-1065890, a second-gen VMAT2 inhibitor, in healthy adults

INBRAIN Neuroelectronics has been awarded a €4 million grant from Spain’s PERTE Chip Program to advance graphene-based brain-computer interfaces

INBRAIN Neuroelectronics has been awarded a €4 million grant from Spain’s PERTE Chip Program to advance graphene-based brain-computer interfaces

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.